Abhijit Shete

505 total citations
23 papers, 340 citations indexed

About

Abhijit Shete is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, Abhijit Shete has authored 23 papers receiving a total of 340 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Rheumatology, 8 papers in Hematology and 8 papers in Immunology. Recurrent topics in Abhijit Shete's work include Spondyloarthritis Studies and Treatments (14 papers), Autoimmune and Inflammatory Disorders Research (8 papers) and Rheumatoid Arthritis Research and Therapies (8 papers). Abhijit Shete is often cited by papers focused on Spondyloarthritis Studies and Treatments (14 papers), Autoimmune and Inflammatory Disorders Research (8 papers) and Rheumatoid Arthritis Research and Therapies (8 papers). Abhijit Shete collaborates with scholars based in Switzerland, United States and United Kingdom. Abhijit Shete's co-authors include Atul Deodhar, Brian Porter, Kwaku Marfo, Mark Lebwohl, Xenofon Baraliakos, Jorge Safi, Luminita Pricop, Iain B. McInnes, Dafna D. Gladman and Philip J. Mease and has published in prestigious journals such as Annals of the Rheumatic Diseases, British Journal of Dermatology and Lara D. Veeken.

In The Last Decade

Abhijit Shete

23 papers receiving 333 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Abhijit Shete Switzerland	11	179	169	84	41	35	23	340
A. Laíz Spain	10	84 0.5×	128 0.8×	49 0.6×	40 1.0×	20 0.6×	45	272
Rik Joos Belgium	11	212 1.2×	266 1.6×	149 1.8×	13 0.3×	24 0.7×	20	453
Magda D’Agostino Italy	8	224 1.3×	123 0.7×	49 0.6×	17 0.4×	87 2.5×	9	337
Nouran Abaza Egypt	11	66 0.4×	130 0.8×	17 0.2×	11 0.3×	13 0.4×	22	227
Rochella A. Ostrowski United States	10	43 0.2×	129 0.8×	35 0.4×	31 0.8×	7 0.2×	14	282
Ignacio García-Valladares United States	10	105 0.6×	126 0.7×	47 0.6×	13 0.3×	8 0.2×	16	252
Giorgia Grosso Sweden	9	205 1.1×	139 0.8×	46 0.5×	29 0.7×	59 1.7×	19	330
Marco Antônio Araújo da Rocha Loures Brazil	10	57 0.3×	102 0.6×	50 0.6×	29 0.7×	7 0.2×	13	267
Claudia Lasagni Italy	12	173 1.0×	30 0.2×	47 0.6×	26 0.6×	170 4.9×	28	325
Dapo Ilo United States	12	55 0.3×	49 0.3×	52 0.6×	7 0.2×	22 0.6×	34	355

Countries citing papers authored by Abhijit Shete

Since Specialization

Citations

This map shows the geographic impact of Abhijit Shete's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abhijit Shete with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abhijit Shete more than expected).

Fields of papers citing papers by Abhijit Shete

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Abhijit Shete. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abhijit Shete. The network helps show where Abhijit Shete may publish in the future.

Co-authorship network of co-authors of Abhijit Shete

This figure shows the co-authorship network connecting the top 25 collaborators of Abhijit Shete. A scholar is included among the top collaborators of Abhijit Shete based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Abhijit Shete. Abhijit Shete is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Marx, Nikolaus, Issei Komuro, Preethy Prasad, et al.. (2024). Awareness and Perceptions towards the Role of Systemic Inflammation and High-Sensitivity C-reactive Protein as a Biomarker in Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease: The Multinational FLAME-ASCVD Survey amongst Cardiologists. Global Heart. 19(1). 98–98. 1 indexed citations

Gottlieb, Alice B., Atul Deodhar, Iain B. McInnes, et al.. (2022). Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data. Acta Dermato Venereologica. 102. adv00698–adv00698. 57 indexed citations

Braun, Jürgen, Ricardo Blanco, Helena Marzo‐Ortega, et al.. (2021). Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT. Arthritis Research & Therapy. 23(1). 231–231. 21 indexed citations

Schett, Georg, Xenofon Baraliakos, Filip Van den Bosch, et al.. (2021). Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies. The Journal of Rheumatology. 48(8). 1251–1258. 11 indexed citations

Kvien, Tore K, Philip G. Conaghan, Laure Gossec, et al.. (2020). Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long‐Term Results of Two Phase III Randomized Controlled Trials. Arthritis Care & Research. 74(5). 759–767. 11 indexed citations

Deodhar, Atul, Iain B. McInnes, Xenofon Baraliakos, et al.. (2020). FRI0272 SECUKINUMAB DEMONSTRATES A CONSISTENT SAFETY PROFILE IN PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS OVER LONG TERM: UPDATED POOLED SAFETY ANALYSES. Annals of the Rheumatic Diseases. 79. 722–722. 4 indexed citations

Deodhar, Atul, Xenofon Baraliakos, Helena Marzo‐Ortega, et al.. (2020). Incidence of Uveitis in Secukinumab‐treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies. ACR Open Rheumatology. 2(5). 294–299. 37 indexed citations

Marzo‐Ortega, Helena, Corinne Miceli‐Richard, P.G.P Machado, et al.. (2020). P248 Subcutaneous secukinumab 150 mg provides rapid and sustained relief in total and nocturnal back pain, morning stiffness and fatigue in patients with active AS over 4 years. Lara D. Veeken. 59(Supplement_2). 1 indexed citations

Elewski, Boni E., John W. Baddley, Atul Deodhar, et al.. (2020). Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis. JAMA Dermatology. 157(1). 43–43. 44 indexed citations

10.

McInnes, Iain B., Dafna D. Gladman, Atul Deodhar, et al.. (2019). Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis. Queensland's institutional digital repository (The University of Queensland). 71. 1 indexed citations

11.

Shete, Abhijit, et al.. (2019). Glycomonoterpene-Functionalized Crack-Resistant Biocompatible Silk Fibroin Coatings for Biomedical Implants. ACS Applied Bio Materials. 2(2). 675–684. 10 indexed citations

12.

McInnes, Iain B., Dafna D. Gladman, Atul Deodhar, et al.. (2019). FRI0401 EFFECT OF LONG-TERM TREATMENT WITH SECUKINUMAB ON LIPID PROFILE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS: POOLED 4 YEAR ANALYSIS. Annals of the Rheumatic Diseases. 78. 886–887. 3 indexed citations

13.

Deodhar, Atul, Dafna D. Gladman, Iain B. McInnes, et al.. (2019). Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis. The Journal of Rheumatology. 47(4). 539–547. 21 indexed citations

14.

Schett, Georg, Xenofon Baraliakos, Filip Van den Bosch, et al.. (2019). FRI0380 SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENT OF ENTHESITIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS: POOLED ANALYSIS OF FOUR PIVOTAL PHASE 3 STUDIES. Annals of the Rheumatic Diseases. 78. 873–874. 4 indexed citations

15.

Deodhar, Atul, Annelies Boonen, Gianfranco Ferraccioli, et al.. (2019). FRI0388 SECUKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS, IRRESPECTIVE OF TIME SINCE FIRST DIAGNOSIS: POOLED RESULTS FROM THE SECUKINUMAB PHASE 3 TRIAL PROGRAM. Annals of the Rheumatic Diseases. 78. 878–879. 5 indexed citations

16.

Deodhar, Atul, Dafna D. Gladman, Iain B. McInnes, et al.. (2018). SAT0271 Secukinumab, a fully human anti-interleukin-17a monoclonal antibody, exhibits low immunogenicity in patients with psoriatic arthritis and ankylosing spondylitis during a 52-week treatment period. Annals of the Rheumatic Diseases. 77. 999–1000. 8 indexed citations

17.

Chawla, Manoj, Tae Ho Kim, Roberto Mirasol, et al.. (2018). Initial combination therapy with vildagliptin plus metformin in drug-naïve patients with T2DM: a 24-week real-life study from Asia. Current Medical Research and Opinion. 34(9). 1605–1611. 8 indexed citations

18.

Assaad‐Khalil, Samir H., et al.. (2015). Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups. Vascular Health and Risk Management. 11. 71–71. 4 indexed citations

19.

Sison, Jorge, et al.. (2014). Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: the EXCITE study. Current Medical Research and Opinion. 30(10). 1937–1945. 15 indexed citations

20.

Shete, Abhijit. (2013). Vildagliptinvssulfonylurea in Indian Muslim diabetes patients fasting during Ramadan. World Journal of Diabetes. 4(6). 358–358. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact